Background To investigate the clinical value of the alpha-fetoprotein (AFP) response
following transcatheter arterial chemoembolization (TACE) in intermediate-stage …

The role of alpha-fetoprotein (AFP) in the specific setting of the diagnosis and prognosis of
patients with hepatocellular cancer (HCC) waiting for liver transplantation (LT) is still …

Background The value of alpha-fetoprotein (AFP) as a prognostic indicator in patients with
hepatocellular carcinoma (HCC) has been proposed in recent studies, but the evidence so …

Background and Aim. The clinical course of hepatocellular carcinoma (HCC) is determined
by cancer‐related and nonrelated factors. We evaluated the effect of a cancer‐related factor …

Nivolumab monotherapy has a modest objective response rate (ORR) in hepatocellular
carcinoma (HCC). To overcome the lack of biomarkers that predict delayed alpha-fetoprotein …

Objective To investigate the effect of negative expression of serum alpha-fetoprotein (AFP)(<
20 ng/L) on the prognosisand staging of patients with hepatocellular carcinoma (HCC), the …

Background Few studies have assessed the relationship between serum alpha-fetoprotein
(AFP) and yttrium-90 (Y-90) radioembolization response in hepatocellular carcinoma (HCC) …

326 Background: REACH-2 (NCT02435433) demonstrated a significant survival benefit with
RAM vs placebo in the second-line treatment of patients with advanced HCC and AFP≥ 400 …

Background Serum lens culinaris agglutinin-reactive fraction of α-fetoprotein (AFP-L3%) has
been widely used for HCC diagnosis and follow-up surveillance as tumor serologic marker …

Background Serum alpha‐fetoprotein (AFP) level is normal in 30–40% of hepatocellular
carcinoma (HCC) patients, and knowledge on its characteristics and clinical outcome is …